The Lautenschlaeger Lab is led by Tim Lautenschlaeger, MD and this team of researchers is working to measure and predict response to radiation therapy in solid tumors with the goal to develop biomarker-guided personalized radiation prescriptions and follow-up care.
Circulating nucleic acid biomarkers are uniquely suitable for cancer detection, therapy response and follow-up monitoring. Moreover, biomarker-guided follow-up strategies after definitive cancer treatment might not only improve outcomes but also address outcomes disparities secondary to access barriers to specialized oncology care.
